CD274 and triple-negative breast carcinoma: Our study sought to characterize PD-L1 expression in immune cells on triple-negative breast cancer tumors and, using a computer-based algorithm, to estimate the risk of PD-L1 status misclassification (false negative and false positive results) in biopsies.